The question? What deal signed in the last 12 months said the most about pharmaâ€™s current situation? The response was the $15.6 billion AstraZeneca is paying for MedImmune. And as the blog describes it, the "driver was product panic." Here a few of the comments they received, which indicate how anxious it's made some people at big pharma...
A big pharma R&D chief: â€œThe deal shows the magnitude of the desperation of the pharmaceutical industry, and how badly things are going right now.â€
The head of business development at a big drugmaker: The price â€œillustrates the general paucity of pipelines in many major companies. Over time, I believe this is a value destruction deal and if replicated too often will lead to trouble.â€
A biotech ceo: â€œBiologics are likely to represent 30 percent of any big pharmaâ€™s future product portfolio and that they have to get in the game now, not via this or that product but, rather, by acquiring a soups-to-nuts biologics capability.â€
To get a different take on the same deal, read these comments by MedImmune ceo David Mott.
Hat tip to the In Vivo Blog